Member Info for belgrano

Boots No:7 is a quality hydrating cream.

What are the ingredients in Boots No7?

INGREDIENTS: Aqua (Water), Glycerin, C12-15 alkyl benzoate, Octocrylene, Butyl methoxydibenzoylmethane, Butylene glycol, Butyrospermum parkii (Shea) butter, Tribehenin, Polyglyceryl-6 Stearate, Dimethicone, Ammonium acryloyldimethyltaurate/VP copolymer, Alcohol denat., Ethylhexyl salicylate, Cetearyl alcohol, Silica, ...

No real scientific claims or additional benefits that I can see. Comparing Apples with Pears compared to Zenakine.

Not cheap either for what you get at around £35 to £70

Hi Cliostock,

I believe its all about the money and the cheapest they can obtain us. Extending the NDA is a clever ploy to keep the shareprice down. If pushed I think they would open fire around 40p, and try to get Stuart on board with sweeteners, and approach our largest holder, whose current dealing sense is questionable, so he might take that offer and infuriate/delight OPTI holders, dependant on your own circumstances.

If rebuffed may just be an opening bid, or tempt in another major player with a raise because on the global scheme of things, there are plenty of bigger fish out there.

Thats when we see decent value like you suggest, and the publicity of such deal will tempt them to throw their caps into the ring.

All the major manufacturers have departments seeking out what the opposition are up to, and whats the latest breakthrough product on the market which they all seek. Its why Croda have secrecy as a top priority with us and at their own production plants. However the launch was open source, and so was our company presentation so you can bet your btm dollar that we are already being investigated for such an opportunity. Those predators will delight in seeing our low market cap and decent chunks held by some weak hands. Other products also seen as a huge bonus.

Its an advantage for any predator right now to move quickly. Wouldn't mind betting that Stuart gets some initial approaches even if informal in next few weeks.

I agree with your comments about value, £2 may be over optimistic but in time which I'm afraid in critically short supply.

Got to consider that we have only had that information about the product clearly explained for one week. Also being fair that's with a aim stock that not many people look at. Throw into the mix one broker with an almost constant sell order from SOH does create a little head wind.

Inversely that's an enormous advantage to the investors here, as the full attributes of the product have been announced it in effect totally changes the game as far as our company are concerned.

Even our company did not know the full results, and are still probably to acknowledge true potential.

Actually an extremely rare find, like finding a "new colour".

Right now we do have "first mover advantage", and being brutally frank, one of the best short term windows I have ever seen, with the CEO holding back royalty payments from us and the market due to the NDA. If case it was missed SA said product orders had been made. Let alone information regarding order pipeline.

I've actually spoken privately to some folks who I know are very knowledgeable in this field and they believe its going to be a block buster.

We all make our own choices and the losses and gains are our own. However well worth reviewing the actual company presentation again if haven't got substack access which is more in depth.

https://www.skinbiotherapeutics.com/investor-relations/company-presentations/

Know many here have also reached similar conclusions as myself.

however credit where credit is due, and i must single out pj (brill investment experience), toyin , alex and elrico, who really does have a nose like a ****house rat, for repeated superb substack presentations.

can't recommend joining enough for those of you who have not done so yet.

we all complete good research and diligence and its easy to think its not worth it, but i guarantee they will be items that join a few dots that you had not considered.

also great insight into other brill prospects, as its not new view of mine but i doubt this company will actually see another christmas.

The additional prize for the greediest shark is clear for every investor who has read the company presentation. Its been discussed here as strangely missed from the presentation and that's suncream, and every product that also accompanies that like skin hydration and repair. A huge market in its own field where Zenakine could be added right now to improve every current cream on the market. Its ripe for the taking, winner takes the whole pot.

All depends on the money, whats great to a new holder buying now, may be poor compared to a long standing shareholder who purchased above say 40p. They do have a robust take over history and a war chest.

Croda isn't the only large formulator out there. Amsterdam was for worldwide specialists and companies to attend.

Those sharks certainly took notice when those product attributes were revealed, and probably participated in the standing ovation.

There is blood everywhere in the water due to our current low price, and the CEO is hamstrung in the water due to the NDA, which may take him a couple of months to break free from.

Investor splashing by revealing strategy, may provoke the first bite very soon. Whether its big enough to kill off and swallow this company with the first bite remains to be seen, as it knows its bigger hungrier brothers are close on its tail, and this prey is a unique rare prize with global applications

Errr no doubts remain Will about the product which is key.

SBTX remain world leaders and getting a product to this stage does take many years so in that point you are correct, but not about the rest.

If you dont know whats unique about Zenakine kindly read the company report, or if you require more laymans terms but better explained Elricos post on substack. Its all there and if you have read it but still disagree you will be embarrassing yourself I'm afraid.

I do believe that Zenakine has taken everyone by surprise including SA. Before the recent Croda announcements this company was bumbling along with low and not overly inspiring sales while those running our company effectively milked it drawing high salaries without putting skin in the game.

With regular share issues/ fund raisers it would have continued to trundle along for years as a company with good potential but not quite getting there. Aim is littered with similar.

Zenakine has instantly changed the game setting a new standard, a new colour so to speak. Customers will probably overwhelm supply and things are about to get really silly.

We will now see Stuart transform to the CEO I think he can be, our company all need to sit down around the table and conduct a new strategic review of where we are going and where the money is to be made.

With such a great product it wont be long before clients start contacting him to do deals with royalties of buy direct. At the same time once the income stream gets revealed he will then get investors looking for stock , which I hope he politely declines but points them in Stevens direction for a major direct purchase. It will be good to get that monkey off our back as signs are that his agent has been offloading still in the last 2 days and beyond.

Then its full steam ahead.

Full agreement PGlancy, Wonder how we can get SOH a free copy of the report because I suspect hes still selling the OPTI holders stock at a time when its simply foolish to do so. Even he would change his opinion by reading it.

That was the last big unknown cleared today, why hes holding back on releasing sales data, cant be for no or low payment. Can only be for the opposite as it gives opposition indication of sales orders. They know the cats out of the bag now is the time for the advertising to start. Press will get it soon.

Just listened to the very latest substack broadcast produced by Elrico. Making real sense of the company announcement today.

I'm simply stunned. Truly excellent work and insight.

(That's coming from an investor who wasn't a subscriber till a few months ago).

Makes me think we should side-line acne work... produce Zenakine under our own white label, now we have the capability.

Its a lot more complicated than it first appears, due to the now "enhanced" properties a higher price point can be commanded.

All formulations have bulk carriers which might be a mix with say a sprinkle of our lysate, which is 3%.

Say a formulation 1000KG IBC sells for £1000 to one of sedermas clients. Firstly we all agree that whatever the client then does with it or sells it for doesn't come into this discussion.

The bulking agent may be very cheap to bulk purchase but clearly our lysate has to be reacted in a bio digester, it s lso the factor which causes the massive increase in price from raw bulk ingredients.

I understood previously our royalty at 10% in this case would be £100 ie 10% of the sale of the IBC to the customer.

However if its only 10% of the lysate base cost, that would be a huge order of magnitude less.

Clearly if you have a mix of very active products it gets more tricky to fairly divide, but as I believed our product was causing higher price points and adding some volume 10% overall royalty seems correct.

Yes think it will work out right, however its important we know the facts about this. If I recall it was a direct answer in a previous presentation by Stuart, as it caused similar ambiguity previously.

Always wondered if they were going to have to pay us so much royalties why not take us out. Wording from Stuart today was this is a natural replacement for matrixyl and retinol, that risk must be high. Due to its large "suite of properties", and no one even mentioned sun protection, it clearly sits in a class of its own. Word will soon spread around the industry and Croda isnt the only shark out there, plus we have agreement to produce the product ourselves...Which I highly doubt will ever happen.

No I know I'm not wrong on this as we previously had it conformed as it caused quite a discussion.

You may recall at that time it was discussed that the pot of whatever would only need a "sprinkle", of our product on it for sale bt Croda to its clients and we would receive double digit royalties on the sale price to the customer, not double digit percentage of the sprinkle.. This is hugely significant and a major F up if SA has been reporting this wrong to us or somehow contractual terms have been altered.

WE have asked this question before a few times and it always came back as double digit royalty of total sales price. I am confident of this fact, unless something has changed?

Product clearly going to be huge, confirms talk that production and orders are in, and sort of confirms some things that we heard from the plant.

Clearly financials are being hidden from us, did wonder why before the report and said either "no orders", but we know thats incorrect or "extremely high amounts of sales", so as not to alert competitor.. Daft really as theyve only got to watch that video to come to the same conclusion as DR. Chahal. We have a new primary colour that can be added to anything.

Hi Whackery, yes that is a very major point and diverges from what SA has told us before, I'm pretty sure of it.

Was always suspicious of being given a broken bat to play with and this definitely needs clarifying.

Before we were told and please correct me if i'm wrong (doh again).

If the formulation containing our lysate gets sold we get double digit royalty on the total sale price to the customer (clearly not any retail price).

Now it sounded like...we get double digit royalty on our product. Hope this is incorrect.

Now we know a "sprinkle" is currently 3%.

So before if product formulation say 1000 kg sell s for £1000 we would get with 10% royalty £100

If we get 10% of our product as royalty its reduced to 10% of 3% of £1000 or £3, from a £1000 sale.

Something smells bad here. Hope I'm wrong or we miss heard.

Something smells bad here.

Ahh well 30 mins till it kicks off.. plenty of time for a megga brew. Look forward to seeing your questions answered properly Toyin . Believe this is going to be important viewing for investors here.

I've ticked you up Oleric.

Unless the plain answer is "no sales". Whatever the reason shareholders should hear the truth. That would be acceptable, not nice but acceptable. Or the opposite "production is struggling to meet demand but I cant give specifics".

I was really hoping for a trading update today, perhaps revealing some sales data specific to Croda. How our product has been reviewed by the many sederma clients would be good information and any "rough guide" on customer uptake a massive advantage but not expected.

Https://www.cosmeticsdesign-europe.com/Article/2025/04/14/whats-new-in-neurocosmetics-ingredients/